Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1994 1
1995 6
1996 4
1997 3
1998 16
1999 13
2000 25
2001 19
2002 31
2003 22
2004 25
2005 34
2006 19
2007 23
2008 19
2009 17
2010 12
2011 11
2012 8
2013 10
2014 8
2015 9
2016 3
2017 1
2018 2
2019 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

333 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Stavudine or zidovudine in three-drug combination therapy for initial treatment of HIV infection in antiretroviral-naive individuals.
Spaulding A, Rutherford GW, Siegfried N. Spaulding A, et al. Cochrane Database Syst Rev. 2010 Aug 4;(8):CD008651. doi: 10.1002/14651858.CD008651. Cochrane Database Syst Rev. 2010. PMID: 20687097 Review.
Two common medications given in first-line antiretroviral therapy are the nucleoside reverse transcriptase inhibitors (NRTI) stavudine (d4T) or zidovudine (AZT). OBJECTIVES: To assess the efficacy of d4T compared to AZT in combination with one NRTI and one non-nucleoside r …
Two common medications given in first-line antiretroviral therapy are the nucleoside reverse transcriptase inhibitors (NRTI) stavudine …
Biologic effects and safety of stavudine: overview of phase I and II clinical trials.
Skowron G. Skowron G. J Infect Dis. 1995 Mar;171 Suppl 2:S113-7. doi: 10.1093/infdis/171.supplement_2.s113. J Infect Dis. 1995. PMID: 7861015 Review.
Data on the biologic effects and safety of stavudine in patients with AIDS and AIDS-related complex represent results of two phase I trials (n = 84), another phase I study of patients with hematologic intolerance to zidovudine (n = 23), and a phase II trial (n = 152). The …
Data on the biologic effects and safety of stavudine in patients with AIDS and AIDS-related complex represent results of two phase I …
Bioequivalence of dispersed stavudine: opened versus closed capsule dosing.
Innes S, Norman J, Smith P, Smuts M, Capparelli E, Rosenkranz B, Cotton M. Innes S, et al. Antivir Ther. 2011;16(7):1131-4. doi: 10.3851/IMP1876. Antivir Ther. 2011. PMID: 22024529 Free PMC article. Clinical Trial.
BACKGROUND: Stavudine, a nucleoside reverse transcriptase inhibitor, is used commonly to treat HIV-infected children in the developing world. ...Stavudine pharmacokinetics were analysed using non-compartmental methods and formulations were compared using ANOVA. ...
BACKGROUND: Stavudine, a nucleoside reverse transcriptase inhibitor, is used commonly to treat HIV-infected children in the developin …
Stavudine but not didanosine as part of HAART contributes to peripheral lipoatrophy: a substudy from the Antiretroviral Regimen Evaluation Study (ARES).
Lowe SH, Hassink EA, van Eck-Smit BL, Borleffs JC, Lange JM, Reiss P. Lowe SH, et al. HIV Clin Trials. 2007 Sep-Oct;8(5):337-44. doi: 10.1310/hct0805-337. HIV Clin Trials. 2007. PMID: 17956835 Clinical Trial.
Patients had been randomized to receive nelfinavir/didanosine/stavudine (n = 8), nevirapine/didanosine/lamivudine (n = 7), or ritonavir-boosted saquinavir/didanosine/lamivudine (n = 4). ...These changes in limb fat were statistically significantly different when comparing …
Patients had been randomized to receive nelfinavir/didanosine/stavudine (n = 8), nevirapine/didanosine/lamivudine (n = 7), or ritonav …
Stavudine, nevirapine and ritonavir in stable antiretroviral therapy-experienced children with human immunodeficiency virus infection.
Yogev R, Lee S, Wiznia A, Nachman S, Stanley K, Pelton S, Mofenson L, Fiscus S, Jimenez E, Rathore MH, Smith ME, Song LY, McIntosh K; Pediatrics AIDS Clinical Trials Group 338 Study Team. Yogev R, et al. Pediatr Infect Dis J. 2002 Feb;21(2):119-25. doi: 10.1097/00006454-200202000-00007. Pediatr Infect Dis J. 2002. PMID: 11840078 Clinical Trial.
BACKGROUND: The efficacy and tolerance of switching from zidovudine (ZDV) and lamivudine (3TC) in clinically stable HIV-infected children with incomplete viral suppression to stavudine (d4T), nevirapine (NVP) and ritonavir (RTV) has not been determined. ...
BACKGROUND: The efficacy and tolerance of switching from zidovudine (ZDV) and lamivudine (3TC) in clinically stable HIV-infected children wi …
Stavudine entry into cerebrospinal fluid after single and multiple doses in patients infected with human immunodeficiency virus.
Brady KA, Boston RC, Aldrich JL, MacGregor RR. Brady KA, et al. Pharmacotherapy. 2005 Jan;25(1):10-7. doi: 10.1592/phco.25.1.10.55625. Pharmacotherapy. 2005. PMID: 15767215 Clinical Trial.
STUDY OBJECTIVE: To establish the pharmacokinetics of stavudine within the cerebrospinal fluid (CSF) of patients infected with human immunodeficiency virus (HIV). ...PATIENTS: Thirty-six patients infected with HIV; 21 were receiving long-term stavudine therapy, 15 w …
STUDY OBJECTIVE: To establish the pharmacokinetics of stavudine within the cerebrospinal fluid (CSF) of patients infected with human …
Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial.
Mulenga V, Musiime V, Kekitiinwa A, Cook AD, Abongomera G, Kenny J, Chabala C, Mirembe G, Asiimwe A, Owen-Powell E, Burger D, McIlleron H, Klein N, Chintu C, Thomason MJ, Kityo C, Walker AS, Gibb DM; CHAPAS-3 trial team. Mulenga V, et al. Lancet Infect Dis. 2016 Feb;16(2):169-79. doi: 10.1016/S1473-3099(15)00319-9. Epub 2015 Oct 5. Lancet Infect Dis. 2016. PMID: 26481928 Free PMC article. Clinical Trial.
FINDINGS: Between Nov 8, 2010, and Dec 28, 2011, 480 children were randomised: 156 to stavudine, 159 to zidovudine, and 165 to abacavir. After two were excluded due to randomisation error, 156 children were analysed in the stavudine group, 158 in the zidovudine grou …
FINDINGS: Between Nov 8, 2010, and Dec 28, 2011, 480 children were randomised: 156 to stavudine, 159 to zidovudine, and 165 to abacav …
Substituting Abacavir for Stavudine in Children Who Are Virally Suppressed Without Lipodystrophy: Randomized Clinical Trial in Johannesburg, South Africa.
Strehlau R, Shiau S, Arpadi S, Patel F, Pinillos F, Tsai WY, Coovadia A, Abrams E, Kuhn L. Strehlau R, et al. J Pediatric Infect Dis Soc. 2018 Aug 17;7(3):e70-e77. doi: 10.1093/jpids/pix110. J Pediatric Infect Dis Soc. 2018. PMID: 29373687 Free PMC article. Clinical Trial.
Few data regarding virologic and metabolic outcomes among children who undergo substitution of stavudine exist. We evaluated the effects of preemptive substitution of abacavir for stavudine in children initially without lipodystrophy and virally suppressed on a s …
Few data regarding virologic and metabolic outcomes among children who undergo substitution of stavudine exist. We evaluated the effe …
Lipid levels, insulin resistance and cardiovascular risk over 96 weeks of antiretroviral therapy: a randomised controlled trial comparing low-dose stavudine and tenofovir.
Vos AG, Chersich MF, Klipstein-Grobusch K, Zuithoff P, Moorhouse MA, Lalla-Edward ST, Kambugu A, Kumarasamy N, Grobbee DE, Barth RE, Venter WD. Vos AG, et al. Retrovirology. 2018 Dec 14;15(1):77. doi: 10.1186/s12977-018-0460-z. Retrovirology. 2018. PMID: 30547820 Free PMC article. Clinical Trial.
We investigated these changes in the first 96 weeks of treatment with low-dose stavudine or tenofovir regimens. METHODS: This is a secondary analysis of a double blind, randomised controlled trial performed in South-Africa, Uganda and India comparing low-dose stavudine …
We investigated these changes in the first 96 weeks of treatment with low-dose stavudine or tenofovir regimens. METHODS: This is a se …
Efficacy and Safety of Tenofovir Disoproxil Fumarate Versus Low-Dose Stavudine Over 96 Weeks: A Multicountry Randomized, Noninferiority Trial.
Venter WDF, Kambugu A, Chersich MF, Becker S, Hill A, Arulappan N, Moorhouse M, Majam M, Akpomiemie G, Sokhela S, Poongulali S, Feldman C, Duncombe C, Ripin DHB, Vos A, Kumarasamy N. Venter WDF, et al. J Acquir Immune Defic Syndr. 2019 Feb 1;80(2):224-233. doi: 10.1097/QAI.0000000000001908. J Acquir Immune Defic Syndr. 2019. PMID: 30640204 Free PMC article. Clinical Trial.
BACKGROUND: Reducing doses of antiretroviral drugs, including stavudine (d4T), may lower toxicity, while preserving efficacy. There are substantial concerns about renal and bone toxicities of tenofovir disoproxil fumarate (TDF). ...
BACKGROUND: Reducing doses of antiretroviral drugs, including stavudine (d4T), may lower toxicity, while preserving efficacy. There a …
333 results